Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Santa Clara, CA – October 29, 2025 – In a historic moment for the technology sector, Nvidia (NASDAQ: NVDA) has officially achieved an unprecedented $5 trillion market capitalization, becoming the first publicly traded company to reach this staggering valuation. This monumental milestone, reached on Wednesday, October 29, 2025, underscores Nvidia's indispensable role
Nvidia (NASDAQ: NVDA) stands as the undisputed titan of the artificial intelligence (AI) era, its stock performance a primary catalyst for the recent, unprecedented surge in global financial markets. As of October 29, 2025, the company's valuation has soared to a historic $5 trillion, a milestone unmatched by any public
NetworkNewsWire Editorial Coverage : The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (“FDA”), along with other regulators for nanocarrier-based delivery technologies used in advanced therapeutics. This accelerating adoption highlights a broader shift across the industry: a race to optimize how medicines are transported, absorbed, and activated within the human body. Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( profile ) is at the forefront of this movement with its proprietary Deciparticle(TM) platform, designed to enhance both the bioavailability and therapeutic index of existing oncology drugs. By improving the performance of underutilized compounds, the technology could help redefine standards for cancer treatment. The company’s recent advancement of Sapu-003 into human trials reflects growing traction for this approach, demonstrating how next-generation delivery science can unlock new therapeutic value and reshape the future of oncology innovation. Oncotelic Therapeutics is committed to making a difference in the global oncology space, positioning itself as an innovator along with other companies working to make a difference in cancer treatment, including Iovance Biotherapeutics Inc . (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and…
Global pharmaceutical company Eli Lilly (NYSE:LLY)
will be announcing earnings results this Thursday before market open. Here’s what investors should know.
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA)
jumped 5.2% in the afternoon session after CEO Jensen Huang laid out an overwhelmingly bullish case for the company's future at a landmark GTC keynote in Washington, D.C.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations.
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a
